Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade D 10.49 -9.88% -1.15
DVAX closed down 9.88 percent on Thursday, December 13, 2018, on 1.24 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DVAX trend table...

Date Alert Name Type % Chg
Dec 13 Fell Below 20 DMA Bearish 0.00%
Dec 13 Fell Below 50 DMA Bearish 0.00%
Dec 13 180 Bearish Setup Bearish Swing Setup 0.00%
Dec 13 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Dec 12 Crossed Above 20 DMA Bullish -9.88%
Dec 12 Crossed Above 50 DMA Bullish -9.88%
Dec 11 NR7 Range Contraction -3.05%
Dec 11 Lower Bollinger Band Walk Weakness -3.05%
Dec 10 Lower Bollinger Band Walk Weakness -3.50%
Dec 10 Lower Bollinger Band Touch Weakness -3.50%

Older signals for DVAX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Is DVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.8
52 Week Low 9.63
Average Volume 1,228,842
200-Day Moving Average 14.631
50-Day Moving Average 11.479
20-Day Moving Average 11.477
10-Day Moving Average 11.013
Average True Range 0.8072
ADX 22.7
+DI 16.3888
-DI 26.0805
Chandelier Exit (Long, 3 ATRs ) 10.2384
Chandelier Exit (Short, 3 ATRs ) 12.5216
Upper Bollinger Band 12.6696
Lower Bollinger Band 10.2844
Percent B (%b) 0.09
BandWidth 20.782434
MACD Line -0.2432
MACD Signal Line -0.1578
MACD Histogram -0.0854
Fundamentals Value
Market Cap 575.26 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -4.33
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.35
Resistance 3 (R3) 12.53 12.08 12.04
Resistance 2 (R2) 12.08 11.61 12.00 11.94
Resistance 1 (R1) 11.29 11.32 11.07 11.11 11.83
Pivot Point 10.84 10.84 10.73 10.76 10.84
Support 1 (S1) 10.05 10.37 9.83 9.87 9.15
Support 2 (S2) 9.60 10.08 9.52 9.04
Support 3 (S3) 8.81 9.60 8.94
Support 4 (S4) 8.63